At the news
? BULLISHIMPACT 6/10 6-K filed May 8, 2026 at 09:00 ET
Alpha Tau completed enrollment of 88 patients in its U.S. pivotal ReSTART trial for Alpha DaRT in recurrent cutaneous squamous cell carcinoma, a key milestone toward potential FDA PMA approval. The company has Breakthrough Device Designation and initiated the modular PMA process in January 2026. No financial data was provided; the event is a clinical milestone with no revenue impact yet.
- Enrolled all 88 patients in the ReSTART pivotal trial for recurrent cSCC
- First U.S. pivotal study to complete enrollment for Alpha Tau
- Alpha DaRT received Breakthrough Device Designation from FDA
- First module of modular PMA application submitted in January 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access